← Surfer · Sage hub

Sage — Metabolic Hypothesis of Diabetes

Named diabetes phenotypes are treated first as long-running compensatory modes when ATP capacity falls short of mismatch load. Stay monist: Shore / Surf Judge language names orientation inside one field — not a second “mind stuff” beside mitochondria, and not a moral story in which sugar invents evil independent of cellular fuel handling.

Introduction: Dashboard readouts vs. engine failure

In the dominant paradigm, type 2 diabetes (and much of the broader dysglycemic spectrum) is defined and managed by its most visible dashboard metrics: elevated fasting glucose, postprandial spikes, HbA1c, and the compensatory hyperinsulinemia or insulin resistance that accompanies them. Treatment algorithms accordingly target these readouts — suppressing hepatic glucose output, enhancing insulin secretion or sensitivity, promoting urinary glucose loss, or providing exogenous insulin. These interventions can lower measured glucose, reduce certain microvascular events in trials, and offer cardiovascular risk modulation in selected populations. Yet they often leave the underlying engine untouched and may trade one set of problems for others: progressive weight trajectories that do not restore flexibility, beta-cell workload that continues or worsens, gastrointestinal effects, hypoglycemia risk, and the lived experience of patients who feel their disease is being managed rather than resolved.

This essay continues the series that has reframed cancer as a primary mitochondrial energy crisis in which genomic instability and the hallmarks of malignancy emerge secondarily; obesity as a defended state arising from engine inefficiency best addressed through deep repair rather than chronic signaling overrides; and chronic disease more broadly as varied downstream expressions of compromised holobiont symbiosis — the frayed partnership between eukaryotic host and its bacterial/archaeal partners, especially the gut biota. Here I propose that diabetes is most coherently understood as a primary deficit in mitochondrial ATP-generating capacity across key tissues. Hyperglycemia and hyperinsulinemia are not the root but downstream compensatory responses to an inadequate match between engine output and metabolic load. This is the metabolic analogue of Coleridge’s ancient mariner:

“Water, water, everywhere,
Nor any drop to drink.”

Abundant glucose circulates in the blood and lipid fuels are stored in abundance within adipocytes and visceral fat depots. Yet mitochondria in muscle, liver, beta cells, endothelium, and other tissues experience relative energy starvation. Insulin resistance, reflecting receptor-level tolerance, limits efficient glucose uptake and disposal into cells, thereby sequestering the primary carbohydrate fuel in the bloodstream. Concurrently, hyperinsulinemia actively suppresses lipolysis, trapping lipid fuels inside fat stores and preventing their release into circulation for mitochondrial β-oxidation. The engine is thus starved of usable substrates precisely because the compensatory hormonal milieu — itself a response to the primary ATP deficit — sequesters those substrates away from the mitochondria that need them. Plenty of fuel exists in the body; it is simply held back from the sites of oxidation and ATP generation. This sequestration creates and sustains the vicious cycle: the more the system compensates by raising insulin and inducing resistance, the less fuel reaches the already compromised mitochondria, further widening the energy mismatch.

The hypothesis does not deny the importance of glucose homeostasis or the utility of existing tools in acute or refractory settings. It simply places them in proper hierarchical context: dashboard adjustments are useful when the engine is failing, but they are not substitutes for restoring the engine itself. The same metabolic optimization strategies that appear across the series — fuel aligned with ancestral patterns and holobiont needs, circadian coherence, hormetic strength, and periodic deep repair — offer a unified path to restore what I have elsewhere termed level 0–1 metabolic persistence: the foundational bioenergetic persistence and striving that underpins all higher-order function.

The primary mechanism: mitochondrial ATP generation deficit

Mitochondria are not merely ATP factories; they are the evolved interfaces where fuel is transduced into the universal energy currency, where redox state is managed, where apoptotic and inflammatory signaling originates, and where much of the cell’s quality-control and adaptive capacity resides. When their capacity to generate ATP efficiently from available substrates falls below demand — or when the quality of that ATP generation is degraded by excessive ROS, backlog, or structural damage — the organism mounts compensatory responses.

In the proposed model, the initiating and sustaining lesion in most type 2 diabetes (and contributing to aspects of other dysglycemic states) is impaired oxidative phosphorylation and fuel oxidation in muscle, liver, beta cells, endothelium, and other insulin-sensitive or high-energy tissues. This can arise from reduced electron transport chain (ETC) efficiency or capacity, impaired pyruvate dehydrogenase (PDH) flux, dysregulated mitochondrial dynamics, suppressed biogenesis, and inflammatory or redox insults that further damage mitochondrial membranes and enzymes.

The result is a cell that can take up glucose (or has it forced upon it) but cannot oxidize it cleanly or completely to CO₂ and H₂O with maximal ATP yield. The cell “starves” in the midst of plenty because the downstream engine is bottlenecked or inefficient. This mismatch between substrate availability and usable energy output is the core lesion.

Two related bioenergetic responses mark the course of that lesion. The Crabtree effect is the reversible suppression of oxidative phosphorylation that occurs in some cells when glucose is abundant; substrate-level phosphorylation rises temporarily while mitochondria remain competent. The Warburg effect is the persistent reliance on aerobic glycolysis and reduced metabolic flexibility that appears when mitochondrial ATP-generating headroom has been eroded and the compensatory program locks in. On this hypothesis, a carbohydrate load in a metabolically flexible person produces the first, and it reverses. Years of load on an engine that cannot keep up may produce the second. Type 2 diabetes may be the systemic record of that progression.

Upstream drivers of the mitochondrial ATP-generating deficit

The mitochondrial inefficiency that initiates this cascade does not arise in a vacuum. It is the predictable downstream consequence of sustained evolutionary mismatch between human (and mitochondrial) physiology and the modern environment. Four converging inputs are especially salient.

First, chronic high refined-carbohydrate load with low fermented microbiota-accessible carbohydrates (MACs) creates persistent substrate pressure on already marginal oxidative capacity while starving the holobiont of the short-chain fatty acids and signaling molecules that support colonocyte and host mitochondrial biogenesis and redox balance. Second, circadian misalignment — artificial light after sunset, irregular feeding windows, and disrupted sleep — abolishes the natural oscillatory repair and biogenesis rhythms that mitochondria require for quality control and hormetic adaptation. Third, insufficient strength and movement-derived hormesis removes the primary stimulus for PGC-1α-driven mitochondrial biogenesis and the dynamic resistance/zone-2 work that maintains oxidative reserve and insulin sensitivity in muscle. Fourth, the cumulative effects of industrial seed oils (peroxidation-prone n-6 PUFAs incorporated into mitochondrial membranes), ultra-processed food additives, and reduced ancestral movement patterns compound membrane damage, inflammatory signaling, and failed mitophagy.

Under these conditions the engine is asked to process a continuous, high-glycemic fuel mix without the intermittent fasting windows, fermentable fibers, or mechanical loading that historically permitted repair, biogenesis, and fuel flexibility. The result is progressive attrition of oxidative phosphorylation capacity, accumulation of damaged mitochondria, and a cell that can take up glucose or store fat but can no longer convert those substrates into ATP at the rate required by tissue demand. Hyperglycemia and hyperinsulinemia then emerge as compensatory readouts, and the sequestration dynamic (receptor tolerance limiting glucose uptake + insulin-mediated suppression of lipolysis) further starves the already compromised mitochondria of usable fuel — exactly the “water, water everywhere” state.

This framing does not deny individual genetic or developmental vulnerability; it simply places those factors in context as modifiers of susceptibility to an environment that systematically erodes mitochondrial integrity.

Hyperglycemia, hyperinsulinemia, and fuel sequestration

Hyperglycemia in this framing is not the primary disease but a downstream signal and compensatory mechanism. Hyperinsulinemia is likewise compensatory — early on overcoming resistance to force storage, later reflecting the high energetic cost of sustained insulin synthesis and secretion on already compromised mitochondria.

The sequestration dynamic sharpens the “water, water everywhere” insight. Insulin resistance at the receptor level keeps glucose fuel sequestered in the blood, unavailable for efficient cellular uptake and mitochondrial oxidation. Hyperinsulinemia simultaneously blocks lipolysis, keeping abundant lipid fuels locked inside adipocytes and visceral fat depots rather than being released as free fatty acids for mitochondrial β-oxidation. The mitochondria are therefore energy-starved not because fuel is absent from the body, but because the compensatory hormonal response to the primary ATP deficit actively sequesters those fuels away from the engine. This is the precise metabolic thirst in the midst of plenty.

Thus the classic vicious cycles of glucotoxicity and lipotoxicity are real but secondary amplifiers. They accelerate damage to an already compromised engine rather than initiating the process de novo. The root remains the mitochondrial ATP-generating deficit; the hormonal and storage responses are the organism’s attempt to manage an engine that cannot keep up with load or efficiently burn what is available.

Tissue-specific expressions and integration with the series

Muscle, liver, beta cells, and endothelium all manifest the same core energy deficit, expressed as insulin resistance, inappropriate gluconeogenesis, beta-cell exhaustion, and microvascular damage (including retinopathy as a retinal energy/redox crisis). In the liver, gluconeogenesis is an ATP-consuming pathway localized to the well-oxygenated periportal zone. On the reading set out in Sage — Hepatology, when mitochondrial headroom is chronically constrained the hepatocyte may not suppress gluconeogenesis appropriately even in the fed state, and fasting hyperglycemia may be the downstream consequence of insufficient oxidative capacity to match the energetic cost of ordered glucose handling. In the kidney the same lock may appear as diabetic kidney disease, where podocytes and proximal tubules progress from reversible Crabtree-like shifts to locked Warburg-like glycolysis and fibrosis (Sage — Nephrology). This unifies with the mitochondrial-metabolic reframing of cancer, the engine-repair model of obesity, and the holobiont compromise underlying broader chronic disease.

Related Good Doctor framing sharpens the eye-shaped end of the same geometry: diabetic retinopathy, in the conventional story, is sugar destroying capillaries. Sugar matters. The retina is also one of the most metabolically active tissues on the body. Pericyte and endothelial failure, capillary dropout, edema, and later neovascularization are the record of cells that cannot keep barriers and flow, then of a compensatory attempt to restore delivery. Anti-VEGF injections treat a downstream angiogenesis; they do not by themselves explain why the retina asked for vessels. That supports reading chronic diabetic eye disease as compensation under energy mismatch — it does not authorize skipping ophthalmology or glucose emergency care from a webpage.

Related diabesity essay pairs the same dashboard/engine claim with obesity and GLP-1 pharmacology: appetite-signal override can improve A1c and weight trajectories while lean mass and engine capacity remain unrestored — a canary, not a proof that the mitochondrial lesion was repaired. Obesity has its own Wipeout page; this page stays on diabetes.

Metabolic optimization strategies to restore level 0–1 metabolic persistence

The same strategies articulated across the series and embodied in the EnSurf mitochondrial optimization framework (Fuel / Circadian / Strength) apply directly and coherently to diabetes. The goal is restoration of the engine’s ability to generate ATP efficiently, clear damage, and regain metabolic flexibility.

Prioritize animal-sourced proteins and fats. Include fermented microbiota-accessible carbohydrates (MACs — sauerkraut, kimchi, fermented vegetables) to nourish the holobiont and generate SCFAs that support mitochondrial function. Strategically restrict refined carbohydrates, avoid industrial seed oils, align circadian rhythms with morning light and proper sleep, and use dynamic resistance training plus zone 2 aerobic work for biogenesis and oxidative capacity. Medically supervised prolonged fasting enables deep autophagy and mitophagy. NAD⁺ precursors, PQQ, CoQ10, and AMPK activators serve as targeted adjuncts. Track grip strength, HRV/readiness, and contextual inflammatory markers as engine-level signals beyond the glucose dashboard.

These interventions do not replace indicated pharmacologic therapy; they may address the upstream mismatch that makes those therapies necessary and reduce the probability that acute Crabtree-like compensations lock into Warburg architecture.

None of this is a self-start protocol. Insulin, SGLT2 inhibitors, GLP-1 agonists, and other agents keep their place in acute and refractory settings. Hypothesis claim: dashboard tools without concurrent engine repair leave capacity unrestored.

Limits of the claim

• Working hypothesis. Not a randomized-trial verdict that mitochondrial-first strategies outperform guideline diabetes care as monotherapy.
• Does not deny glucose toxicity, microvascular trial benefits of glycemic control, or the clinical utility of insulin, GLP-1 RAs, SGLT2i, metformin, and related agents when indicated.
• Does not claim unsupervised prolonged fasting, extreme carbohydrate elimination, or supplements reverse diabetes or replace endocrinology clocks.
• Does not invent Type 1 pathophysiology as identical to Type 2; the core essay centers Type 2 / dysglycemic spectrum with mitochondrial ATP deficit as primary lesion — Type 1 remains autoimmune beta-cell loss with its own clocks.
• No dualism.

Conclusion: Restoring the engine

The metabolic hypothesis of diabetes places primary mitochondrial ATP generation deficit at the root, with hyperglycemia, hyperinsulinemia, insulin resistance, beta-cell failure, and complications as downstream expressions and amplifiers. The upstream drivers — chronic high refined-carbohydrate load with low fermented MACs, circadian misalignment, insufficient strength hormesis, and industrial dietary insults — systematically erode the mitochondrial capacity that evolved under intermittent, hormetic, ancestrally aligned conditions. When the engine cannot efficiently convert abundant fuel into usable energy, the organism compensates with dashboard signals and storage behaviors — including receptor tolerance that sequesters glucose in blood and blocked lipolysis that traps lipids in fat stores — that appear pathological only when viewed in isolation.

Suppressing those signals without restoring capacity trades short-term metric improvement for long-term engine decline. The same optimization strategies that restore level 0–1 metabolic persistence across the series — ancestrally aligned fuel and holobiont support, circadian coherence, hormetic strength, and strategic deep repair — directly reverse the drivers that created the deficit in the first place. In an era of rising metabolic disease despite ever more sophisticated dashboard pharmacology, returning to the engine may prove both more frugal and more effective. The water is still everywhere. The task is to repair the capacity to drink.

This essay builds directly on The Mitochondrial-Metabolic Hypothesis of Cancer, the Metabolic Hypothesis of Obesity Management via Prolonged Fasting, and the Metabolic Hypothesis of Eukaryote–Gut Biota Symbiosis. It is offered in the same spirit of first-principles integration and collaborative refinement. Coach and Surfer give shorter versions. Endocrinology and primary care still own diagnosis, glucose emergencies, and medication clocks.

A working hypothesis, open to correction and revised as new evidence arrives. Last revised October 23, 2026.

See the notice at the top of this page. Working hypothesis, not medical advice. Essay draws from peer-reviewed mechanisms in mitochondrial biology, diabetes metabolism, and related clinical observation as of 2026 — individual care requires personalized evaluation by a qualified physician.